532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
| Autor: | Glas, A., Peeters, J., Yau, C., Wolf, D.M., Sanil, A., Li, Y., Severson, T., Linn, S., Buxton, M., DeMichele, A., Hylton, N., Symmans, F., Yee, D., Paoloni, M., Esserman, L., Berry, D., Rugo, H., Olopade, O., van 't Veer, L.J. |
|---|---|
| Zdroj: | In European Journal of Cancer November 2014 50 Supplement 6:173-173 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect